MPP and International Diabetes Federation join forces to improve access to diabetes medicines
Hepatitis C drugs, available as generics through MPP’s licence, show early promising results for COVID-19
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries.
Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with ten patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals and a tuberculosis treatment. MPP was founded by Unitaid, which serves as sole funder for MPP’s activities in HIV, hepatitis C and tuberculosis.
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
countries have benefitted from access to MPP-licensed products
ongoing pharmaceutical development projects
Billion dollars saved by the international community, from January 2012 to December 2019
Billion doses of treatment supplied to date
Million patient-years of treatment through MPP’s generic partners, from January 2012 to December 2019
For Everyone Everywhere
Discover where we helped and what we have achieved
#Tuberculosis is the 🌍’s top infectious disease killer & leading cause of death for people living w/#HIV. This #WorldLungDay 🫁 & every day, MPP recognises the value of increasing #access to #affordable treatments 💊 for #TB & continues to strive towards making it into a reality https://t.co/JYBSHOK4Jx
👉MPP is looking forward to being part of @WHO_Europe Regional meeting today on #TB, #HIV and viral #hepatitis & is delighted to continue supporting countries & partners in the #EECA region @ECDC_EU @MasoudDara @Kazatchkine @UNAIDS @EATGx @GlobalFund https://t.co/fkosT1f2l5
📖#ReadingNow: 2020 update of @EASLnews Recommendations on Treatment of #HepC now available! ✅Generic DAAs produced by MPP partners are recognised as being as effective as the original compounds ✅Generic SOF/DAC seen as an appropriate option in #LMICs https://t.co/lVh9vlS6yv
Martina Penazzato @penazzatom1
Learn about the evolution of the Global Accelerator for Paediatric Formulations (GAP-f) as it is being relaunched as a @WHO Network. Register at https://t.co/tNUmsZjfkU #Paediatrics #BetterDrugs4Kids @CHAI_health @Penta_ID @MedsPatentPool @EGPAF https://t.co/cgM882zVj7
Today marks the #WorldPatientSafetyDay. Recognising #PatientSafety as a #GlobalHealth priority, MPP & partners strive to make #QualityAssured affordable medicines available for all who need them. #Safe & #effective meds are key to ensuring patient safety. #Access2Meds #UHC https://t.co/BGi9GJHGf5
DRV/r is a @WHO-recommended 2nd line treatment for #HIV. Yet, its generic #paediatric fixed-dose version is unavailable. MPP welcomes & supports @CHAI_health @Unitaid #RFP for development of the 💊 into a child-friendly formulation. Calling out our #generic partners to apply! https://t.co/hzzIqdVsYl